Plain-English translation of NCT05636787 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Multiple Myeloma research guide →Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether combining with — the current standard chemotherapy drugs given before a stem cell transplant — works better than alone for treating multiple myeloma. The goal is to see if this new medication combination helps prevent the cancer from coming back after transplantation, while keeping side effects manageable.
Most myeloma patients relapse even after stem cell transplantation with standard chemotherapy. Researchers are looking for ways to make the treatment stronger and more effective without causing too much harm to the body.
You likely qualify if…
You likely don't qualify if…
You would be randomly assigned to receive either the new two-drug chemotherapy combination or the standard single-drug chemotherapy. Both groups receive the drugs over several days before undergoing a stem cell transplant. You will have regular hospital visits for chemotherapy administration, monitoring, and recovery, with close medical supervision during and after your transplant.
AI-generated summary from trial data · Jun 4, 2026 · Not medical advice
Switzerland
Phase
Testing effectiveness
Sponsor
Insel Gruppe AG, University Hospital Bern
Enrollment target
~120 participants
Started
June 2023
Primary completion
January 2028
Age range
18 Years – 75 Years
Last updated on clinicaltrials.gov in July 2024.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Thomas Pabst, Prof Dr. med
Department for Medical Oncology; University Hospital/Inselspital
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.